The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 31 January 2006, www.theannals.com, DOI 10.1345/aph.1G363.
 The Annals of Pharmacotherapy: Vol. 40, No. 2, pp. 332-335. DOI 10.1345/aph.1G363
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kilickap, S.
Right arrow Articles by Tekuzman, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kilickap, S.
Right arrow Articles by Tekuzman, G.

Nonconvulsive Status Epilepticus Due to Ifosfamide

Saadettin Kilickap, MD

Clinical Fellow, Department of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey

Mustafa Cakar, MD

Assistant, Department of Internal Medicine, Hacettepe University Institute Faculty of Medicine, Ankara

Ibrahim K Onal, MD

Assistant, Department of Internal Medicine, Hacettepe University Institute Faculty of Medicine

Abdurrahman Tufan, MD

Assistant, Department of Internal Medicine, Hacettepe University Institute Faculty of Medicine

Hadim Akoglu, MD

Assistant, Department of Internal Medicine, Hacettepe University Institute Faculty of Medicine

Sercan Aksoy, MD

Clinical Fellow, Department of Medical Oncology, Hacettepe University Institute of Oncology

Mustafa Erman, MD

Associate Professor, Department of Medical Oncology, Hacettepe University Institute of Oncology

Gulten Tekuzman, MD

Professor, Department of Medical Oncology, Hacettepe University Institute of Oncology

Reprints: Dr. Kilickap, Department of Medical Oncology, Hacettepe University Institute of Oncology, Sihhiye 06100, Ankara, Turkey, fax 90 312 309 2905, skilickap{at}yahoo.com

OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.

CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE. One woman received ifosfamide 1000 mg/m2 (1 h infusion on days 1–5); confusion, lethargy, and speech deterioration developed on day 3. The second patient developed similar symptoms on day 3 of treatment with 2500 mg/m2. Both patients responded to intravenous administration of diazepam 10 mg and were given levetiracetam as maintenance therapy.

DISCUSSION: The severity and presentation of central nervous system toxicity due to ifosfamide varies greatly and involves a spectrum ranging from subclinical electroencephalogram changes to coma. NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide. Levetiracetam may be used for maintenance antiepileptic therapy after diazepam administration.

CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent. An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.

Key Words: ifosfamide, levetiracetam, nonconvulsive status epilepticus

Published Online, January 31, 2006. www.theannals.com, DOI 10.1345/aph.1G363




homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.